DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic …

ABSTRACT Interleukin-2 (IL-2) is one of the key cytokines with pleiotropic effects on immune
system. It has been approved for the treatment of metastatic renal cell carcinoma and …

Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …

Cardiac glycosides (CGs) are natural compounds sharing the ability to operate as potent
inhibitors of the plasma membrane Na+/K+-ATPase, hence promoting—via an indirect …

Melanoma is a skin cancer with permanently increasing incidence and resistance to
therapies in advanced stages. Reports of spontaneous regression and tumour infiltration …

In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …

Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An
early stage melanoma can be surgically removed, with a survival rate of 99%. However …

Introduction There is currently no curative treatment for melanoma once the disease spreads
beyond the original site. Although activation of the PI3K/Akt pathway resulting from genetic …

In patients with malignancy, the major barrier to achieving complete response is emergence
of resistance to current chemotherapeutic agents. One of the major mechanisms by which …

Melanoma, the most aggressive skin cancer that originated from genetic mutations in the
melanocytes, is still a troublesome medical problem under the current therapeutic …